Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Breast Cancer Research
Erschienen in: Breast Cancer Research 3/2010

01.06.2010 | Review

Tumour-associated carbohydrate antigens in breast cancer

verfasst von: Aurélie Cazet, Sylvain Julien, Marie Bobowski, Joy Burchell, Philippe Delannoy

Erschienen in: Breast Cancer Research | Ausgabe 3/2010

Einloggen, um Zugang zu erhalten

Abstract

Glycosylation changes that occur in cancer often lead to the expression of tumour-associated carbohydrate antigens. In breast cancer, these antigens are usually associated with a poor prognosis and a reduced overall survival. Cellular models have shown the implication of these antigens in cell adhesion, migration, proliferation and tumour growth. The present review summarizes our current knowledge of glycosylation changes (structures, biosynthesis and occurrence) in breast cancer cell lines and primary tumours, and the consequences on disease progression and aggressiveness. The therapeutic strategies attempted to target tumour-associated carbohydrate antigens in breast cancer are also discussed.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
2.
Le Marer N, Laudet V, Svensson EC, Cazlaris H, Van Hille B, Lagrou C, Stehelin D, Montreuil J, Verbert A, Delannoy P: The c-Ha-ras oncogene induces increased expression of beta-galactoside alpha-2, 6-sialyltransferase in rat fibroblast (FR3T3) cells. Glycobiology. 1992, 2: 49-56. 10.1093/glycob/2.1.49.CrossRefPubMed
3.
Buckhaults P, Chen L, Fregien N, Pierce M: Transcriptional regulation of N-acetylglucosaminyltransferase V by the src oncogene. J Biol Chem. 1997, 272: 19575-19581. 10.1074/jbc.272.31.19575.CrossRefPubMed
4.
Narita T, Funahashi H, Satoh Y, Watanabe T, Sakamoto J, Takagi H: Association of expression of blood group-related carbohydrate antigens with prognosis in breast cancer. Cancer. 1993, 71: 3044-3053. 10.1002/1097-0142(19930515)71:10<3044::AID-CNCR2820711026>3.0.CO;2-R.CrossRefPubMed
5.
Soares R, Marinho A, Schmitt F: Expression of sialyl-Tn in breast cancer. Correlation with prognostic parameters. Pathol Res Pract. 1996, 192: 1181-1186.CrossRefPubMed
6.
Ura Y, Dion AS, Williams CJ, Olsen BD, Redfield ES, Ishida M, Herlyn M, Major PP: Quantitative dot blot analyses of blood-group-related antigens in paired normal and malignant human breast tissues. Int J Cancer. 1992, 50: 57-63. 10.1002/ijc.2910500113.CrossRefPubMed
7.
Miles DW, Happerfield LC, Smith P, Gillibrand R, Bobrow LG, Gregory WM, Rubens RD: Expression of sialyl-Tn predicts the effect of adjuvant chemotherapy in node-positive breast cancer. Br J Cancer. 1994, 70: 1272-1275.CrossRefPubMedPubMedCentral
8.
Hebbar M, Krzewinski-Recchi MA, Hornez L, Verdiere A, Harduin-Lepers A, Bonneterre J, Delannoy P, Peyrat JP: Prognostic value of tumoral sialyltransferase expression and circulating E-selectin concentrations in node-negative breast cancer patients. Int J Biol Markers. 2003, 18: 116-122.PubMed
9.
Recchi MA, Hebbar M, Hornez L, Harduin-Lepers A, Peyrat JP, Delannoy P: Multiplex reverse transcription polymerase chain reaction assessment of sialyltransferase expression in human breast cancer. Cancer Res. 1998, 58: 4066-4070.PubMed
10.
Julien S, Adriaenssens E, Ottenberg K, Furlan A, Courtand G, Vercoutter-Edouart AS, Hanisch FG, Delannoy P, Le Bourhis X: ST6GalNAc I expression in MDA-MB-231 breast cancer cells greatly modifies their O-glycosylation pattern and enhances their tumourigenicity. Glycobiology. 2006, 16: 54-64. 10.1093/glycob/cwj033.CrossRefPubMed
11.
Julien S, Lagadec C, Krzewinski-Recchi MA, Courtand G, Le Bourhis X, Delannoy P: Stable expression of sialyl-Tn antigen in T47-D cells induces a decrease of cell adhesion and an increase of cell migration. Breast Cancer Res Treat. 2005, 90: 77-84. 10.1007/s10549-004-3137-3.CrossRefPubMed
12.
Bos PD, Zhang XH, Nadal C, Shu W, Gomis RR, Nguyen DX, Minn AJ, van de Vijver MJ, Gerald WL, Foekens JA, Massagué J: Genes that mediate breast cancer metastasis to the brain. Nature. 2009, 459: 1005-1009. 10.1038/nature08021.CrossRefPubMedPubMedCentral
13.
Cazet A, Groux-Degroote S, Teylaert B, Kwon KM, Lehoux S, Slomianny C, Kim CH, Le Bourhis X, Delannoy P: GD3 synthase overexpression enhances proliferation and migration of MDA-MB-231 breast cancer cells. Biol Chem. 2009, 390: 601-609. 10.1515/BC.2009.054.CrossRefPubMed
14.
Rakha EA, Boyce RW, Abd El-Rehim D, Kurien T, Green AR, Paish EC, Robertson JF, Ellis IO: Expression of mucins (MUC1, MUC2, MUC3, MUC4, MUC5AC and MUC6) and their prognostic significance in human breast cancer. Mod Pathol. 2005, 18: 1295-1304. 10.1038/modpathol.3800445.CrossRefPubMed
15.
Hanisch FG, Uhlenbruck G, Peter-Katalinic J, Egge H, Dabrowski J, Dabrowski U: Structures of neutral O-linked polylactosaminoglycans on human skim milk mucins. A novel type of linearly extended poly-N-acetyllactosamine backbones with Gal beta(1-4)GlcNAc beta(1-6) repeating units. J Biol Chem. 1989, 264: 872-883.PubMed
16.
Croce MV, Isla-Larrain M, Rabassa ME, Demichelis S, Colussi AG, Crespo M, Lacunza E, Segal-Eiras A: Lewis x is highly expressed in normal tissues: a comparative immunohistochemical study and literature revision. Pathol Oncol Res. 2007, 13: 130-138. 10.1007/BF02893488.CrossRefPubMed
17.
Muller S, Hanisch FG: Recombinant MUC1 probe authentically reflects cell-specific O-glycosylation profiles of endogenous breast cancer mucin. High density and prevalent core 2-based glycosylation. J Biol Chem. 2002, 277: 26103-26112. 10.1074/jbc.M202921200.CrossRefPubMed
18.
Abecassis J, Collard R, Eber M, Pusel J, Fricker JP, Methlin G: Proteinases and sialyltransferase in human breast tumors. Int J Cancer. 1984, 33: 821-824. 10.1002/ijc.2910330617.CrossRefPubMed
19.
Springer GF: T and Tn, general carcinoma autoantigens. Science. 1984, 224: 1198-1206. 10.1126/science.6729450.CrossRefPubMed
20.
Springer GF, Desai PR, Murthy MS, Scanlon EF: Human carcinoma-associated precursor antigens of the NM blood group system. J Surg Oncol. 1979, 11: 95-106. 10.1002/jso.2930110204.CrossRefPubMed
21.
Schmitt FC, Figueiredo P, Lacerda M: Simple mucin-type carbohydrate antigens (T, sialosyl-T, Tn and sialosyl-Tn) in breast carcinogenesis. Virchows Arch. 1995, 427: 251-258. 10.1007/BF00203391.CrossRefPubMed
22.
Tachibana K, Nakamura S, Wang H, Iwasaki H, Maebara K, Cheng L, Hirabayashi J, Narimatsu H: Elucidation of binding specificity of Jacalin toward O-glycosylated peptides: quantitative analysis by frontal affinity chromatography. Glycobiology. 2006, 16: 46-53. 10.1093/glycob/cwj038.CrossRefPubMed
23.
Wu AM, Wu JH, Yang Z, Singh T, Goldstein IJ, Sharon N: Differential contributions of recognition factors of two plant lectins, Amaranthus caudatus lectin and Arachis hypogea agglutinin, reacting with Thomsen-Friedenreich disaccharide (Galβ1-3GalNAcα1-Ser/Thr). Biochimie. 2008, 90: 1769-1780. 10.1016/j.biochi.2008.08.001.CrossRefPubMed
24.
Lotan R, Skutelsky E, Danon D, Sharon N: The purification, composition, and specificity of the anti-T lectin from peanut (Arachis hypogaea). J Biol Chem. 1975, 250: 8518-8523.PubMed
25.
Pereira ME, Kabat EA, Lotan R, Sharon N: Immunochemical studies on the specificity of the peanut (Arachis hypogaea) agglutinin. Carbohydr Res. 1976, 51: 107-118. 10.1016/S0008-6215(00)84040-9.CrossRefPubMed
26.
Hanisch FG, Baldus SE: The Thomsen-Friedenreich (TF) antigen: a critical review on the structural, biosynthetic and histochemical aspects of a pancarcinoma-associated antigen. Histol Histopathol. 1997, 12: 263-281.PubMed
27.
Cao Y, Stosiek P, Springer GF, Karsten U: Thomsen-Friedenreich-related carbohydrate antigens in normal adult human tissues: a systematic and comparative study. Histochem Cell Biol. 1996, 106: 197-207. 10.1007/BF02484401.CrossRefPubMed
28.
Schindlbeck C, Jeschke U, Schulze S, Karsten U, Janni W, Rack B, Krajewski S, Sommer H, Friese K: Prognostic impact of Thomsen-Friedenreich tumor antigen and disseminated tumor cells in the bone marrow of breast cancer patients. Breast Cancer Res Treat. 2007, 101: 17-25. 10.1007/s10549-006-9271-3.CrossRefPubMed
29.
Schindlbeck C, Jeschke U, Schulze S, Karsten U, Janni W, Rack B, Sommer H, Friese K: Characterisation of disseminated tumor cells in the bone marrow of breast cancer patients by the Thomsen-Friedenreich tumor antigen. Histochem Cell Biol. 2005, 123: 631-637. 10.1007/s00418-005-0781-6.CrossRefPubMed
30.
Glinsky VV, Glinsky GV, Glinskii OV, Huxley VH, Turk JR, Mossine VV, Deutscher SL, Pienta KJ, Quinn TP: Intravascular metastatic cancer cell homotypic aggregation at the sites of primary attachment to the endothelium. Cancer Res. 2003, 63: 3805-3811.PubMed
31.
Yu LG, Andrews N, Zhao Q, McKean D, Williams JF, Connor LJ, Gerasimenko OV, Hilkens J, Hirabayashi J, Kasai K, Rhodes JM: Galectin-3 interaction with Thomsen-Friedenreich disaccharide on cancer-associated MUC1 causes increased cancer cell endothelial adhesion. J Biol Chem. 2007, 282: 773-781. 10.1074/jbc.M606862200.CrossRefPubMed
32.
33.
Ju T, Cummings RD: Protein glycosylation: chaperone mutation in Tn syndrome. Nature. 2005, 437: 1252-10.1038/4371252a.CrossRefPubMed
34.
Ju T, Lanneau GS, Gautam T, Wang Y, Xia B, Stowell SR, Willard MT, Wang W, Xia JY, Zuna RE, Laszik Z, Benbrook DM, Hanigan MH, Cummings RD: Human tumor antigens Tn and sialyl Tn arise from mutations in Cosmc. Cancer Res. 2008, 68: 1636-1646. 10.1158/0008-5472.CAN-07-2345.CrossRefPubMed
35.
Yoo NJ, Kim MS, Lee SH: Absence of COSMC gene mutations in breast and colorectal carcinomas. Apmis. 2008, 116: 154-155. 10.1111/j.1600-0463.2008.00965.x.CrossRefPubMed
36.
Piller V, Piller F, Cartron JP: Comparison of the carbohydrate-binding specificities of seven N-acetyl-D-galactosamine-recognizing lectins. Eur J Biochem. 1990, 191: 461-466. 10.1111/j.1432-1033.1990.tb19144.x.CrossRefPubMed
37.
Brooks SA: The involvement of Helix pomatia lectin (HPA) binding N-acetylgalactosamine glycans in cancer progression. Histol Histopathol. 2000, 15: 143-158.PubMed
38.
Springer GF: Immunoreactive T and Tn epitopes in cancer diagnosis, prognosis, and immunotherapy. J Mol Med. 1997, 75: 594-602. 10.1007/s001090050144.CrossRefPubMed
39.
Wang BL, Springer GF, Carlstedt SC: Quantitative computerized image analysis of Tn and T (Thomsen-Friedenreich) epitopes in prognostication of human breast carcinoma. J Histochem Cytochem. 1997, 45: 1393-1400.CrossRefPubMed
40.
Korourian S, Siegel E, Kieber-Emmons T, Monzavi-Karbassi B: Expression analysis of carbohydrate antigens in ductal carcinoma in situ of the breast by lectin histochemistry. BMC Cancer. 2008, 8: 136-10.1186/1471-2407-8-136.CrossRefPubMedPubMedCentral
41.
Konska G, Guerry M, Caldefie-Chezet F, De Latour M, Guillot J: Study of the expression of Tn antigen in different types of human breast cancer cells using VVA-B4 lectin. Oncol Rep. 2006, 15: 305-310.PubMed
42.
Kawaguchi T, Takazawa H, Imai S, Morimoto J, Watanabe T, Kanno M, Igarashi S: Expression of Vicia villosa agglutinin (VVA)-binding glycoprotein in primary breast cancer cells in relation to lymphatic metastasis: is atypical MUC1 bearing Tn antigen a receptor of VVA?. Breast Cancer Res Treat. 2006, 98: 31-43. 10.1007/s10549-005-9115-6.CrossRefPubMed
43.
Brooks SA, Leathem AJ: Prediction of lymph node involvement in breast cancer by detection of altered glycosylation in the primary tumour. Lancet. 1991, 338: 71-74. 10.1016/0140-6736(91)90071-V.CrossRefPubMed
44.
Leathem AJ, Brooks SA: Predictive value of lectin binding on breast-cancer recurrence and survival. Lancet. 1987, 1: 1054-1056. 10.1016/S0140-6736(87)90482-X.CrossRefPubMed
45.
Danussi C, Coslovi A, Campa C, Mucignat MT, Spessotto P, Uggeri F, Paoletti S, Colombatti A: A newly generated functional antibody identifies Tn antigen as a novel determinant in the cancer cell-lymphatic endothelium interaction. Glycobiology. 2009, 19: 1056-1067. 10.1093/glycob/cwp085.CrossRefPubMedPubMedCentral
46.
van Vliet SJ, Saeland E, van Kooyk Y: Sweet preferences of MGL: carbohydrate specificity and function. Trends Immunol. 2008, 29: 83-90. 10.1016/j.it.2007.10.010.CrossRefPubMed
47.
Saeland E, van Vliet SJ, Backstrom M, van den Berg VC, Geijtenbeek TB, Meijer GA, van Kooyk Y: The C-type lectin MGL expressed by dendritic cells detects glycan changes on MUC1 in colon carcinoma. Cancer Immunol Immunother. 2007, 56: 1225-1236. 10.1007/s00262-006-0274-z.CrossRefPubMed
48.
Napoletano C, Rughetti A, Agervig Tarp MP, Coleman J, Bennett EP, Picco G, Sale P, Denda-Nagai K, Irimura T, Mandel U, Clausen H, Frati L, Taylor-Papadimitriou J, Burchell J, Nuti M: Tumor-associated Tn-MUC1 glycoform is internalized through the macrophage galactose-type C-type lectin and delivered to the HLA class I and II compartments in dendritic cells. Cancer Res. 2007, 67: 8358-8367. 10.1158/0008-5472.CAN-07-1035.CrossRefPubMed
49.
Julien S, Delannoy P: Sialyl-Tn antigen in cancer: from diagnosis to therapy. Recent Research Developments in Cancer. Edited by: Pandalai SG. 2003, Kerala: Transworld Research Network, 5: 185-199.
50.
Julien S, Krzewinski-Recchi MA, Harduin-Lepers A, Gouyer V, Huet G, Le Bourhis X, Delannoy P: Expression of sialyl-Tn antigen in breast cancer cells transfected with the human CMP-Neu5Ac: GalNAc alpha2,6-sialyltransferase (ST6GalNac I) cDNA. Glycoconj J. 2001, 18: 883-893. 10.1023/A:1022200525695.CrossRefPubMed
51.
Sewell R, Backstrom M, Dalziel M, Gschmeissner S, Karlsson H, Noll T, Gatgens J, Clausen H, Hansson GC, Burchell J, Taylor-Papadimitriou J: The ST6GalNAc-I sialyltransferase localizes throughout the Golgi and is responsible for the synthesis of the tumor-associated sialyl-Tn O-glycan in human breast cancer. J Biol Chem. 2006, 281: 3586-3594. 10.1074/jbc.M511826200.CrossRefPubMed
52.
Gold DV, Mattes MJ: Monoclonal antibody B72.3 reacts with a core region structure of O-linked carbohydrates. Tumour Biol. 1988, 9: 137-144. 10.1159/000217554.CrossRefPubMed
53.
Reddish MA, Jackson L, Koganty RR, Qiu D, Hong W, Longenecker BM: Specificities of anti-sialyl-Tn and anti-Tn monoclonal antibodies generated using novel clustered synthetic glycopeptide epitopes. Glycoconj J. 1997, 14: 549-560. 10.1023/A:1018576224062.CrossRefPubMed
54.
Ogata S, Koganty R, Reddish M, Longenecker BM, Chen A, Perez C, Itzkowitz SH: Different modes of sialyl-Tn expression during malignant transformation of human colonic mucosa. Glycoconj J. 1998, 15: 29-35. 10.1023/A:1006935331756.CrossRefPubMed
55.
Kinney AY, Sahin A, Vernon SW, Frankowski RF, Annegers JF, Hortobagyi GN, Buzdar AU, Frye DK, Dhingra K: The prognostic significance of sialyl-Tn antigen in women treated with breast carcinoma treated with adjuvant chemotherapy. Cancer. 1997, 80: 2240-2249. 10.1002/(SICI)1097-0142(19971215)80:12<2240::AID-CNCR4>3.0.CO;2-Y.CrossRefPubMed
56.
Leivonen M, Nordling S, Lundin J, von Boguslawski K, Haglund C: STn and prognosis in breast cancer. Oncology. 2001, 61: 299-305. 10.1159/000055337.CrossRefPubMed
57.
Clement M, Rocher J, Loirand G, Le Pendu J: Expression of sialyl-Tn epitopes on beta1 integrin alters epithelial cell phenotype, proliferation and haptotaxis. J Cell Sci. 2004, 117 (Pt 21): 5059-5069. 10.1242/jcs.01350.CrossRefPubMed
58.
Julien S, Picco G, Sewell R, Vercoutter-Edouart AS, Tarp M, Miles D, Clausen H, Taylor-Papadimitriou J, Burchell JM: Sialyl-Tn vaccine induces antibodymediated tumour protection in a relevant murine model. Br J Cancer. 2009, 100: 1746-1754. 10.1038/sj.bjc.6605083.CrossRefPubMedPubMedCentral
59.
Ravn V, Dabelsteen E: Tissue distribution of histo-blood group antigens. Apmis. 2000, 108: 1-28. 10.1034/j.1600-0463.2000.d01-1.x.CrossRefPubMed
60.
Kaneko M, Kudo T, Iwasaki H, Ikehara Y, Nishihara S, Nakagawa S, Sasaki K, Shiina T, Inoko H, Saitou N, Narimatsu H: Alpha1,3-fucosyltransferase IX (Fuc-TIX) is very highly conserved between human and mouse; molecular cloning, characterization and tissue distribution of human Fuc-TIX. FEBS Lett. 1999, 452: 237-242. 10.1016/S0014-5793(99)00640-7.CrossRefPubMed
61.
Mollicone R, Gibaud A, Francois A, Ratcliffe M, Oriol R: Acceptor specificity and tissue distribution of three human alpha-3-fucosyltransferases. Eur J Biochem. 1990, 191: 169-176. 10.1111/j.1432-1033.1990.tb19107.x.CrossRefPubMed
62.
Natsuka S, Gersten KM, Zenita K, Kannagi R, Lowe JB: Molecular cloning of a cDNA encoding a novel human leukocyte alpha-1,3-fucosyltransferase capable of synthesizing the sialyl Lewis x determinant. J Biol Chem. 1994, 269: 16789-16794.PubMed
63.
Kitagawa H, Paulson JC: Cloning and expression of human Gal beta 1,3(4) GlcNAc alpha 2,3-sialyltransferase. Biochem Biophys Res Commun. 1993, 194: 375-382. 10.1006/bbrc.1993.1830.CrossRefPubMed
64.
Ellies LG, Sperandio M, Underhill GH, Yousif J, Smith M, Priatel JJ, Kansas GS, Ley K, Marth JD: Sialyltransferase specificity in selectin ligand formation. Blood. 2002, 100: 3618-3625. 10.1182/blood-2002-04-1007.CrossRefPubMed
65.
Kukowska-Latallo JF, Larsen RD, Nair RP, Lowe JB: A cloned human cDNA determines expression of a mouse stage-specific embryonic antigen and the Lewis blood group alpha(1,3/1,4)fucosyltransferase. Genes Dev. 1990, 4: 1288-1303. 10.1101/gad.4.8.1288.CrossRefPubMed
66.
Sasaki K, Kurata K, Kojima N, Kurosawa N, Ohta S, Hanai N, Tsuji S, Nishi T: Expression cloning of a GM3-specific alpha-2,8-sialyltransferase (GD3 synthase). J Biol Chem. 1994, 269: 15950-15956.PubMed
67.
Maly P, Thall A, Petryniak B, Rogers CE, Smith PL, Marks RM, Kelly RJ, Gersten KM, Cheng G, Saunders TL, Camper SA, Camphausen RT, Sullivan FX, Isogai Y, Hindsgaul O, von Andrian UH, Lowe JB: The alpha(1,3)fucosyltransferase Fuc-TVII controls leukocyte trafficking through an essential role in L-, E-, and P-selectin ligand biosynthesis. Cell. 1996, 86: 643-653. 10.1016/S0092-8674(00)80137-3.CrossRefPubMed
68.
Renkonen J, Paavonen T, Renkonen R: Endothelial and epithelial expression of sialyl Lewis(x) and sialyl Lewis(a) in lesions of breast carcinoma. Int J Cancer. 1997, 74: 296-300. 10.1002/(SICI)1097-0215(19970620)74:3<296::AID-IJC11>3.0.CO;2-A.CrossRefPubMed
69.
Matsuura N, Narita T, Mitsuoka C, Kimura N, Kannagi R, Imai T, Funahashi H, Takagi H: Increased level of circulating adhesion molecules in the sera of breast cancer patients with distant metastases. Jpn J Clin Oncol. 1997, 27: 135-139. 10.1093/jjco/27.3.135.CrossRefPubMed
70.
Jeschke U, Mylonas I, Shabani N, Kunert-Keil C, Schindlbeck C, Gerber B, Friese K: Expression of sialyl lewis X, sialyl Lewis A, E-cadherin and cathepsin-D in human breast cancer: immunohistochemical analysis in mammary carcinoma in situ, invasive carcinomas and their lymph node metastasis. Anticancer Res. 2005, 25: 1615-1622.PubMed
71.
Nakagoe T, Fukushima K, Itoyanagi N, Ikuta Y, Oka T, Nagayasu T, Ayabe H, Hara S, Ishikawa H, Minami H: Expression of ABH/Lewis-related antigens as prognostic factors in patients with breast cancer. J Cancer Res Clin Oncol. 2002, 128: 257-264. 10.1007/s00432-002-0334-5.CrossRefPubMed
72.
Matsuura N, Narita T, Hiraiwa N, Hiraiwa M, Murai H, Iwase T, Funahashi H, Imai T, Takagi H, Kannagi R: Gene expression of fucosyl- and sialyl-transferases which synthesize sialyl Lewisx, the carbohydrate ligands for E-selectin, in human breast cancer. Int J Oncol. 1998, 12: 1157-1164.PubMed
73.
Hsu CC, Lin TW, Chang WW, Wu CY, Lo WH, Wang PH, Tsai YC: Soyasaponin-Imodified invasive behavior of cancer by changing cell surface sialic acids. Gynecol Oncol. 2005, 96: 415-422. 10.1016/j.ygyno.2004.10.010.CrossRefPubMed
74.
Idikio HA, Manickavel V: Lewis blood group antigens (a and b) in human breast tissues. Loss of Lewis-b in breast cancer cells and correlation with tumor grade. Cancer. 1991, 68: 1303-1308. 10.1002/1097-0142(19910915)68:6<1303::AID-CNCR2820680620>3.0.CO;2-2.CrossRefPubMed
75.
Abd Hamid UM, Royle L, Saldova R, Radcliffe CM, Harvey DJ, Storr SJ, Pardo M, Antrobus R, Chapman CJ, Zitzmann N, Robertson JF, Dwek RA, Rudd PM: A strategy to reveal potential glycan markers from serum glycoproteins associated with breast cancer progression. Glycobiology. 2008, 18: 1105-1118. 10.1093/glycob/cwn095.CrossRefPubMed
76.
Kurebayashi J, Nomura T, Hirono M, Okubo S, Udagawa K, Shiiki S, Ikeda M, Nakashima K, Tanaka K, Sonoo H: Combined measurement of serum sialyl Lewis X with serum CA15-3 in breast cancer patients. Jpn J Clin Oncol. 2006, 36: 150-153. 10.1093/jjco/hyi235.CrossRefPubMed
77.
Hellstrom I, Garrigues HJ, Garrigues U, Hellstrom KE: Highly tumor-reactive, internalizing, mouse monoclonal antibodies to Le(y)-related cell surface antigens. Cancer Res. 1990, 50: 2183-2190.PubMed
78.
Madjd Z, Parsons T, Watson NF, Spendlove I, Ellis I, Durrant LG: High expression of Lewis y/b antigens is associated with decreased survival in lymph node negative breast carcinomas. Breast Cancer Res. 2005, 7: R780-R787. 10.1186/bcr1305.CrossRefPubMedPubMedCentral
79.
Kelly MP, Lee FT, Smyth FE, Brechbiel MW, Scott AM: Enhanced efficacy of 90Y-radiolabeled anti-Lewis Y humanized monoclonal antibody hu3S193 and paclitaxel combined-modality radioimmunotherapy in a breast cancer model. J Nucl Med. 2006, 47: 716-725.PubMed
80.
Pinho SS, Reis CA, Gartner F, Alpaugh ML: Molecular plasticity of E-cadherin and sialyl lewis x expression, in two comparative models of mammary tumorigenesis. PLoS One. 2009, 4: e6636-10.1371/journal.pone.0006636.CrossRefPubMedPubMedCentral
81.
Tettamanti G: Ganglioside/glycosphingolipid turnover: new concepts. Glycoconj J. 2004, 20: 301-317. 10.1023/B:GLYC.0000033627.02765.cc.CrossRefPubMed
82.
Marquina G, Waki H, Fernandez LE, Kon K, Carr A, Valiente O, Perez R, Ando S: Gangliosides expressed in human breast cancer. Cancer Res. 1996, 56: 5165-5171.PubMed
83.
Oliva JP, Valdes Z, Casaco A, Pimentel G, Gonzalez J, Alvarez I, Osorio M, Velazco M, Figueroa M, Ortiz R, Escobar X, Orozco M, Cruz J, Franco S, Díaz M, Roque L, Carr A, Vázquez AM, Mateos C, Rubio MC, Pérez R, Fernández LE: Clinical evidences of GM3 (NeuGc) ganglioside expression in human breast cancer using the 14F7 monoclonal antibody labelled with (99m)Tc. Breast Cancer Res Treat. 2006, 96: 115-121. 10.1007/s10549-005-9064-0.CrossRefPubMed
84.
Ruckhaberle E, Rody A, Engels K, Gaetje R, von Minckwitz G, Schiffmann S, Grosch S, Geisslinger G, Holtrich U, Karn T, Kaufmann M: Microarray analysis of altered sphingolipid metabolism reveals prognostic significance of sphingosine kinase 1 in breast cancer. Breast Cancer Res Treat. 2008, 112: 41-52. 10.1007/s10549-007-9836-9.CrossRefPubMed
85.
Ruckhaberle E, Karn T, Rody A, Hanker L, Gatje R, Metzler D, Holtrich U, Kaufmann M: Gene expression of ceramide kinase, galactosyl ceramide synthase and ganglioside GD3 synthase is associated with prognosis in breast cancer. J Cancer Res Clin Oncol. 2009, 135: 1005-1013. 10.1007/s00432-008-0536-6.CrossRefPubMed
86.
Gu Y, Zhang J, Mi W, Yang J, Han F, Lu X, Yu W: Silencing of GM3 synthase suppresses lung metastasis of murine breast cancer cells. Breast Cancer Res. 2008, 10: R1-10.1186/bcr1841.CrossRefPubMedPubMedCentral
87.
Goss PE, Baker MA, Carver JP, Dennis JW: Inhibitors of carbohydrate processing: a new class of anticancer agents. Clin Cancer Res. 1995, 1: 935-944.PubMed
88.
Paszkiewicz-Gadek A, Porowska H, Lemancewicz D, Wolczynski S, Gindzienski A: The influence of N- and O-glycosylation inhibitors on the glycosylation profile of cellular membrane proteins and adhesive properties of carcinoma cell lines. Int J Mol Med. 2006, 17: 669-674.PubMed
89.
Tanaka T, Decuzzi P, Cristofanilli M, Sakamoto JH, Tasciotti E, Robertson FM, Ferrari M: Nanotechnology for breast cancer therapy. Biomed Microdevices. 2009, 11: 49-63. 10.1007/s10544-008-9209-0.CrossRefPubMed
90.
Lo NW, Dennis JW, Lau JT: Overexpression of the alpha2,6-sialyltransferase, ST6Gal I, in a low metastatic variant of a murine lymphoblastoid cell line is associated with appearance of a unique ST6Gal I mRNA. Biochem Biophys Res Commun. 1999, 264: 619-621. 10.1006/bbrc.1999.1562.CrossRefPubMed
91.
Taniguchi A: Promoter structure and transcriptional regulation of human beta-galactoside alpha2, 3-sialyltransferase genes. Curr Drug Targets. 2008, 9: 310-316. 10.2174/138945008783954998.CrossRefPubMed
92.
Glinsky VV, Huflejt ME, Glinsky GV, Deutscher SL, Quinn TP: Effects of Thomsen-Friedenreich antigen-specific peptide P-30 on betagalactoside-mediated homotypic aggregation and adhesion to the endothelium of MDA-MB-435 human breast carcinoma cells. Cancer Res. 2000, 60: 2584-2588.PubMed
93.
Heimburg J, Yan J, Morey S, Glinskii OV, Huxley VH, Wild L, Klick R, Roy R, Glinsky VV, Rittenhouse-Olson K: Inhibition of spontaneous breast cancer metastasis by anti-Thomsen-Friedenreich antigen monoclonal antibody JAA-F11. Neoplasia. 2006, 8: 939-948. 10.1593/neo.06493.CrossRefPubMedPubMedCentral
94.
Fernandez LE, Alonso DF, Gomez DE, Vazquez AM: Ganglioside-based vaccines and anti-idiotype antibodies for active immunotherapy against cancer. Expert Rev Vaccines. 2003, 2: 817-823. 10.1586/14760584.2.6.817.CrossRefPubMed
95.
Vazquez AM, Gabri MR, Hernandez AM, Alonso DF, Beausoleil I, Gomez DE, Perez R: Antitumor properties of an anti-idiotypic monoclonal antibody in relation to N-glycolyl-containing gangliosides. Oncol Rep. 2000, 7: 751-756.PubMed
96.
Fuentes D, Avellanet J, Garcia A, Iglesias N, Gabri MR, Alonso DF, Vazquez AM, Perez R, Montero E: Combined therapeutic effect of a monoclonal antiidiotype tumor vaccine against NeuGc-containing gangliosides with chemotherapy in a breast carcinoma model. Breast Cancer Res Treat. 2010, 120: 379-389. 10.1007/s10549-009-0399-9.CrossRefPubMed
97.
Diaz A, Alfonso M, Alonso R, Saurez G, Troche M, Catala M, Diaz RM, Perez R, Vazquez AM: Immune responses in breast cancer patients immunized with an anti-idiotype antibody mimicking NeuGc-containing gangliosides. Clin Immunol. 2003, 107: 80-89. 10.1016/S1521-6616(03)00036-6.CrossRefPubMed
98.
Guthmann MD, Castro MA, Cinat G, Venier C, Koliren L, Bitton RJ, Vazquez AM, Fainboim L: Cellular and humoral immune response to N-Glycolyl-GM3 elicited by prolonged immunotherapy with an anti-idiotypic vaccine in high-risk and metastatic breast cancer patients. J Immunother. 2006, 29: 215-223. 10.1097/01.cji.0000188502.11348.34.CrossRefPubMed
99.
Miles D, Papazisis K: Rationale for the clinical development of STn-KLH (Theratope) and anti-MUC-1 vaccines in breast cancer. Clin Breast Cancer. 2003, 3 (Suppl 4): S134-S138. 10.3816/CBC.2003.s.002.CrossRefPubMed
100.
Slovin SF, Ragupathi G, Fernandez C, Diani M, Jefferson MP, Wilton A, Kelly WK, Morris M, Solit D, Clausen H, Livingston P, Scher HI: A polyvalent vaccine for high-risk prostate patients: 'are more antigens better?'. Cancer Immunol Immunother. 2007, 56: 1921-1930. 10.1007/s00262-007-0335-y.CrossRefPubMed
Metadaten
Titel
Tumour-associated carbohydrate antigens in breast cancer
verfasst von
Aurélie Cazet
Sylvain Julien
Marie Bobowski
Joy Burchell
Philippe Delannoy
Publikationsdatum
01.06.2010
Verlag
BioMed Central
Erschienen in
Breast Cancer Research / Ausgabe 3/2010
Elektronische ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr2577

Weitere Artikel der Ausgabe 3/2010

Breast Cancer Research 3/2010 Zur Ausgabe

Editorial

Managing bone mineral density with oral bisphosphonate therapy in women with breast cancer receiving adjuvant aromatase inhibition

Research article

The role of chemotherapeutic drugs in the evaluation of breast tumour response to chemotherapy using serial FDG-PET

Research article

Inhibition of phosphatidylcholine-specific phospholipase C downregulates HER2 overexpression on plasma membrane of breast cancer cells

Research article

Molecular subtypes of breast cancer are associated with characteristic DNA methylation patterns

Letter

Association between the spread of circulating tumor cells and breast cancer subtypes

Research article

Genomic subtypes of breast cancer identified by array-comparative genomic hybridization display distinct molecular and clinical characteristics

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

23.04.2024 Medikamente in Schwangerschaft und Stillzeit Nachrichten

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise